Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DESs (drug-eluting) in Spain: 60% by end 2005:

This article was originally published in Clinica

Executive Summary

By the end of 2005, around 60% of all coronary artery stents implanted in Spain will be drug-eluting (DESs) - up from a current estimated 35-40%. This is according to a study by Dr Eulogio Garcia, head of the department of haemodynamics at Madrid's Gregorio Maranon hospital. The study also found that around 35% of all Spanish implantees of bare metal stents (not drug-eluting) require surgery due to restenosis within six months of the initial operation, reports El Pais.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts